



## **TRACON Pharmaceuticals to Present at the UBS Global Healthcare Conference**

**San Diego, CA – May 11, 2015** – TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the UBS Global Healthcare Conference at 3:00 pm EDT on Monday, May 18, 2015, at the Sheraton New York Times Square Hotel in New York, NY.

To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at [www.traconpharma.com](http://www.traconpharma.com). A replay of the webcast will be available on the website for 30 days following the event.

### **About TRACON**

TRACON develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON’s current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies. To learn more about TRACON and its product candidates, visit TRACON's website at [www.traconpharma.com](http://www.traconpharma.com).

#### Contact:

Casey Logan

Chief Business Officer

(858) 550-0780 ext. 236

[clogan@traconpharma.com](mailto:clogan@traconpharma.com)